F-group (family)
2.2.1.2 Enterotoxin_b
Ligands and drugs
468
Member domains
322
with ligand contacts (≤ 4 Å)
68.8% of members
304
with DrugDomain annotations
65.0% of members
225
with a DrugBank compound
48.1% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 2.2.1.2 belongs to X-group 2 OB-fold, which binds 7.0 ligand superclasses per 20 proteins, narrower than 59% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03709 | BCN | Bicine | 70 |
| DB04473 | FUC | alpha-L-fucose | 49 |
| DB02213 | GAA | Metanitrophenyl-Alpha-D-Galactoside | 15 |
| DB03283 | FUL | beta-L-fucose | 10 |
| DB03446 | AI1 | N-Benzyl-3-(alpha-D-galactopyranosyloxy)benzamide | 10 |
| DB03421 | I06 | 2-Phenethyl-2,3-Dihydro-Phthalazine-1,4-Dione | 6 |
| DB02572 | BV4 | 1,3-bis-([3-[3-[3-(4-{3-[3-nitro-5-(galactopyranosyloxy)-benzoylamino]-propyl}-piperazin-1-yl)-propylamino-3,4-dioxo-cyclobutenyl]-amino-propoxy-ethoxy-ethoxy]-propyl-]amino-carbonyloxy)-2-amino-propane | 5 |
| DB02574 | BV2 | BV2 | 5 |
| DB02802 | FNG | 3-(alpha-D-Galactopyranosyloxy)-5-nitrobenzamide | 5 |
| DB02903 | BV3 | 1,3-bis-([[3-(4-{3-[3-nitro-5-(galactopyranosyloxy)-benzoylamino]-propyl}-piperazin-1-yl)-propylamino-3,4-dioxo-cyclobutenyl]-amino-ethyl]-amino-carbonyloxy)-2-amino-propane | 5 |
| DB03077 | LNQ | 3-Amino-4-{3-[2-(2-Propoxy-Ethoxy)-Ethoxy]-Propylamino}-Cyclobut-3-Ene-1,2-Dione | 5 |
| DB03242 | GAT | P-Aminophenyl-Alpha-D-Galactopyranoside | 5 |
| DB03524 | J12 | N-[3-[4-(3-aminopropyl)piperazin-1-yl]propyl]-3-[(2-thiophen-2-ylacetyl)amino]-5-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzamide | 5 |
| DB04040 | 1DM | N-[1,3-Di(4-morpholinyl)-2-propanyl]-3-(α-D-galactopyranosyloxy)-5-nitrobenzamide | 5 |
| DB04210 | BV1 | 3-(alpha-D-galactopyranosyloxy)-N-(3-{4-[3-({2-[(3-{4-[3-({[3-(hexopyranosyloxy)-5-nitrophenyl]carbonyl}amino)propyl]piperazin-1-yl}propyl)amino]-3,4-dioxocyclobut-1-en-1-yl}amino)propyl]piperazin-1-yl}propyl)-5-nitrobenzamide | 5 |
| DB03793 | BEZ | Benzoic acid | 4 |
| DB04073 | 15B | N-{3-[4-(3-amino-propyl)-piperazin-1-yl]-propyl}-3-nitro-5-(galactopyranosyl)-beta-benzamide | 4 |
| DB03235 | J15 | N-{3-[4-(3-aminopropyl)piperazin-1-yl]propyl}-3-(alpha-D-galactopyranosyloxy)-5-nitrobenzamide | 3 |
| DB00141 | NAG | N-Acetylglucosamine | 2 |
| DB02474 | 233 | BMSC-0013 | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CAmetal | CALCIUM ION | 74 |
| BCN | BICINE | 70 |
| GAL | beta-D-galactopyranose | 66 |
| GLA | alpha-D-galactopyranose | 34 |
| FUC | alpha-L-fucopyranose | 19 |
| A32 | (3-NITRO-5-(3-MORPHOLIN-4-YL-PROPYLAMINOCARBONYL)PHENYL)-GALACTOPYRANOSIDE | 15 |
| GAA | 3-nitrophenyl alpha-D-galactopyranoside | 15 |
| NAmetal | SODIUM ION | 13 |
| CL | CHLORIDE ION | 12 |
| AI1 | N-BENZYL-3-(ALPHA-D-GALACTOS-1-YL)-BENZAMIDE | 10 |
| FUL | beta-L-fucopyranose | 10 |
| 7BN | (2~{R},4~{S},5~{R},6~{R})-5-acetamido-2-[4-[3-[2-[(2~{S},3~{R},4~{R},5~{R},6~{R})-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]ethylamino]-3-oxidanylidene-propyl]-1,2,3-triazol-1-yl]-4-oxidanyl-6-[(1~{R},2~{R})-1,2,3-tris(oxidanyl)propyl]oxane-2-carboxylic acid | 6 |
| I06 | 2-PHENETHYL-2,3-DIHYDRO-PHTHALAZINE-1,4-DIONE | 6 |
| 1DM | N-(2-MORPHOLIN-4-YL-1-MORPHOLIN-4-YLMETHYL-ETHYL)-3-NITRO-5-(3,4,5-TRIHYDROXY-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-2-YLOXY)-BENZAMIDE | 5 |
| 7DB | (2~{R},4~{S},5~{R},6~{R})-5-acetamido-2-[4-[(2~{S})-3-[2-[(2~{S},3~{R},4~{R},5~{R},6~{R})-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]ethylamino]-3-oxidanylidene-2-(2-phenylethanoylamino)propyl]-1,2,3-triazol-1-yl]-4-oxidanyl-6-[(1~{R},2~{R})-1,2,3-tris(oxidanyl)propyl]oxane-2-carboxylic acid | 5 |
| A24 | (3-NITRO-5-(2-MORPHOLIN-4-YL-ETHYLAMINOCARBONYL)PHENYL)-GALACTOPYRANOSIDE | 5 |
| BV1 | [3-(4-{3-[3-NITRO-5-(GALACTOPYRANOSYLOXY)-BENZOYLAMINO]-PROPYL}-PIPERAZIN-1-YL)-PROPYLAMINO] -2-(3-{4-[3-(3-NITRO-5-[GALACTOPYRANOSYLOXY]-BENZOYLAMINO)-PROPYL]-PIPERAZIN-1-YL} -PROPYL-AMINO)-3,4-DIOXO-CYCLOBUTENE | 5 |
| BV2 | 1,3-BIS-([3-(4-{3-[3-NITRO-5-(GALACTOPYRANOSYLOXY)-BENZOYLAMINO]-PROPYL}-PIPERAZIN-1-YL)-PROPYL-AMINO]-CARBONYLOXY)-2-AMINO-PROPANE | 5 |
| BV3 | 1,3-BIS-([[3-(4-{3-[3-NITRO-5-(GALACTOPYRANOSYLOXY)-BENZOYLAMINO]-PROPYL}-PIPERAZIN-1-YL)-PROPYLAMINO-3,4-DIOXO-CYCLOBUTENYL]-AMINO-ETHYL]-AMINO-CARBONYLOXY)-2-AMINO-PROPANE | 5 |
| BV4 | 1,3-BIS-([3-[3-[3-(4-{3-[3-NITRO-5-(GALACTOPYRANOSYLOXY)-BENZOYLAMINO]-PROPYL}-PIPERAZIN-1-YL)-PROPYLAMINO-3,4-DIOXO-CYCLOBUTENYL]-AMINO-PROPOXY-ETHOXY-ETHOXY]-PROPYL-]AMINO-CARBONYLOXY)-2-AMINO-PROPANE | 5 |